sc-222326

This is a cell-permeable naphthyridinyl-phenolic compound which selectively enhances cytokine-induced STAT1 transcription activity, but not STAT3 or NF-˚B transcription activity. It is shown to prolong INF-g-induced tyrosine phosphorylation of STAT1 in NIH3T3 cells and accentuate the STAT1-dependent growth inhibition in MCF-7 and 2fTGH cancer cells.

25 mg

sc-200615

A potential anti-inflammatory agent, thought to act through the irreversible inhibition of cytokine-inducible IBα phosphorylation, leading to the inactivation of NF-κB

10 mg/50 mg/5 mg

sc-200800

Derived from propolis, and shown to have anti-carcinogenic, anti-inflammatory, and immunomodulatory properties; as well as potent NF-κB inhibition.

20 mg/100 mg

sc-203083

IKK-2 inhibitor IV is a potent inhibitor of IKK-2 which interferes with NF-κB DNA binding and therefore expression of many inflammatory genes.

500 µg

sc-3575

Cell-permeable, potent, selective, irreversible 20S proteasome inhibitor. Induces apoptosis in U937 and neurite growth in Neuro 2a.

200 µg/1 mg

sc-204818

Thiazoloamide compound experimentally shown to inhibit TNF-alpha-stimulated NF-κB activation and MMP-9 in HT1080 upregulation.

5 mg

sc-3523

Inhibits expression of COX-2, TNF-α, and IL-1 in LPS-stimulated macrophages; inhibits NFκB and activation of MAP kinase.

50 mg/250 mg

sc-203216

10 mg

sc-200675

Inhibtis the activation of the transcription factor NF-κB and has been used to investigate NF-κB signaling.

1 mg

sc-203241

Immunosuppressant. Potent inhibitor of NF-κB activation. Suppresses cytokine production (IFN-γ, TNF-α, IL-2 and IL-4).

100 µg

sc-202793

A derivative of Rocaglamide with apoptotic effects on leukemic cells, leukemic T cells, inhibiton of NF-κB in non-leukemic T cells as well as insecticide activity towards the larvae Spodoptera littoralis.

50 µg

sc-202321

Derivative of rocaglamide with similar pharmacological properties.

50 µg

sc-351846

The ubiquitin-proteasome pathway plays an integral role in the selective degradation of intracellular proteins. While important for clearing damaged or misfolded proteins, this proteolytic pathway also regulates the availability of key proteins involved in the control of inflammatory processes, cell cycle regulation, and gene expression. (R)-MG132 is a potent, reversible and cell permeable proteasome inhibitor. After treatment for one hour at 100 nM, it inhibits 50% and 31% of proteasome activity in lysates of J558L multiple myeloma cells and EMT6 breast cancer cells, respectively. The (R)-MG132 stereoisomer is a more effective inhibitor of chymotrypsin-like (ChTL), trypsin-like (TL), and peptidylglutamyl peptide hydrolyzing proteasome (PGPH) activities compared to (S)-MG132 (IC50s = 0.22 µM versus 0.89 µM (ChTL); 34.4 µM versus 104.43 µM (TL); 2.95 µM versus 5.70 µM (PGPH), respectively).

1 mg/5 mg

sc-200122

An immunosuppressive, antiinflammatory antibiotic from Tripterygium wilfordii Hook F herb extracts. Activates caspases, promoting apoptosis in T lymphocytes and rheumatoid synovial fibroblasts.

1 mg/5 mg